In March，completed Pre-A financing of RMB 10 million

Signed a cooperation agreement with Rundu Pharma

In May, The second product, a nanocrystalline drugs,

entered GMP pilot production，preparing for phase 1 clinical trials

In August, completed fed BE clinical trial for the first product.

In November，completed Pre-A+ financing of RMB 10 million.

In August，completed Angel round financing of RMB 20 million Completed "nanocrystalline drugs" and "nano Solid dispersion" technology platforms

In October，completed the BE clinical trials for the first product Developed four preclinical nanocrystalline anticancer drugs

In June, completed a 2000 square meter R&D laboratory construction

In September，signed a research cooperation with Macau University of Science and Technology

In October，completed the pre-BE clinical trials for the first product